Clear link between UK’s AstraZeneca vaccine and blood clots: EU health agency
There is a clear link between the coronavirus vaccine produced by British drug company AstraZeneca and rare blood clots in the brain, a senior official for the European Medicines Agency (EMA) said in an interview published on Tuesday.
"In my opinion we can now say it, it is clear that there is an association with the vaccine. However, we still do not know what causes this reaction," Marco Cavaleri, chair of the vaccine evaluation team at the EMA, told Italian daily Il Messaggero when asked about the possible relation between the AstraZeneca shot and cases of brain blood clots.
Cavaleri added that the EMA would say there is a link although the regulator would not likely be in a position this week to give an indication regarding the age of individuals to whom the AstraZeneca shot should be given.
The regulator is investigating 44 reports of a rare brain clotting ailment known as cerebral venous sinus thrombosis (CVST) out of 9.2 million people in the European Economic Area who have received the AstraZeneca vaccine.
AstraZeneca has previously denied any link between blood clots because of its vaccine.
A high proportion among the reported cases affected young and middle-aged women but that did not lead EMA to conclude this cohort was particularly at risk from AstraZeneca's shot.
Some countries, including France, Germany and the Netherlands, have suspending the use of the vaccine in younger people while the investigations continue.
Scientists are exploring several possibilities that might explain the extremely rare brain blood clots that occurred in individuals in the days and weeks after receiving the AstraZeneca vaccine.